// App-Quantinova.ai

: Phase 2 study of the efficacy and safety of erdafitinib in patients (pts) with bacillus Calmette-Guérin (BCG)-unresponsive, high-risk non–muscle-invasive bladder cancer (HR-NMIBC) with FGFR3/2 alterations (alt) in THOR-2: Cohort 2 interim analysis results.

Researchers

Presenter

  • James W.F. Catto

Principal Investigators

  • Viraj A. Master

  • Morgan Roupret

  • Geraldine Pignot

  • Andrea Tubaro

  • Nobuaki Shimizu

  • Nikhil Vasdev

  • Jürgen E. Gschwend

  • Yohann Loriot

  • Hiroyuki Nishiyama

  • Joan Redorta

  • Siamak Daneshmand

  • Yuji Miura

  • Vahid Naini

  • Lauren Crow

  • Spyros Triantos

  • Mahadi Baig

  • Gary D. Steinberg

Medical Centers

  • Lister Hospital, East and North Herts NHS Trust, Stevenage and University of Hertfordshire, Hatfield, United Kingdom

  • Emory University, Atlanta, GA

  • NYU Langone Health, New York, NY

  • Gustave Roussy, Villejuif, France

  • University of Southern California, Los Angeles, CA

  • University of Sheffield, Sheffield, United Kingdom

  • University of Tsukuba, Tsukuba, Japan

  • Technical University of Munich, University Hospital Rechts der Isar, Munich, Germany

  • Janssen Research & Development, San Diego, CA

  • Gunma Prefectural Cancer Center, Ota, Japan

  • Institut Paoli-Calmettes, Marseille, France

  • Hôpital La Salpêtrière, Paris, France

  • Autonomous University of Spain, Barcelona, Spain

  • S. Andrea Hospital, Rome, Italy

  • Toranomon Hospital, Tokyo, Japan

  • Peter MacCallum Cancer Centre, East Melbourne, Australia

Locations

  • Germany

  • Italy

  • France

  • Japan

  • Spain

  • Australia

  • United Kingdom

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Bladder Cancer

Biomarkers

  • Fibroblast growth factor receptor 3

  • Hormone receptor

Drug/Treatment

  • L-Tyrosine

Outcome

  • N/A

Study Design

  • Cohort

Phase

  • II

Study Id's

  • NCT04172675

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved